{"name":"Basilea Pharmaceutica","slug":"basilea-pharmaceutica","ticker":"","exchange":"","domain":"basileapharmaceutica.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQV0UyeS1CU2FCUC1jWVN1VHJYUUNfTGkyeHg0QjNfQlktZjVCRnRfa0FXNVBISVJSMTU1VGNsYkQ5c3VtbEtVY1o1czZvMGg2MW1GdzZMRERJY0p0NDFzRjFOQ1V5di02RzlHdE9SUDFYVjVSNjFoVzFHTlZDUGtNMmhYeG5JTDMyUmFBcTQ5RTlsSi0yaVRXUFkzd1B3WTVMUzEzZ3dhblkySmxZcDVYc3ZEZzFoNUxYcXVDb1hB?oc=5","date":"2026-01-07","type":"deal","source":"European Biotechnology Magazine","summary":"Basilea strikes up to $48.5m antifungal deal with U.S. biotech Prokaryotics - European Biotechnology Magazine","headline":"Basilea strikes up to $48.5m antifungal deal with U.S. biotech Prokaryotics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmdVa3ItTkoyVUZTWmlCbXFhc21LNlJtV0QyWFJlRlY1MnVXWVhUNUFTbjh2TWpUQlJTb1E3Tm5RN1lqcnJaaDFhM0x4eGJnSEdLaUQtWDNkdjEzbEQ1NDRWSjVaVDltdHNhbmVFR3JUR0xYdG5iYUcwNWR4UDB2M1hMajhld1FZelhTejVOdkdYMjZjYUxXNGFpQ0tOZTkwVlZxa2VDMkY?oc=5","date":"2026-01-07","type":"pipeline","source":"The Pharma Letter","summary":"Basilea teams with Prokaryotics on first-in-class antifungals - The Pharma Letter","headline":"Basilea teams with Prokaryotics on first-in-class antifungals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOT29FYXlJR1JTbnk1LUthQlF0bU9CT0l0UDRRaVhFeG1rbkpPWUptV0dVXzZvbXNHRko0VVhJZjNySFYwbm1PTGlLNmJrNXh6YnVQdTRhaVBOY1MydHN1VXJvaVdGcWpMRzc0VnlQendXaDlreDdmZmlUYXNyNWRHN2M4SFl5Rmd1U2FKVEp3S3FCdi03SUljbEdoV3FEc2NrSnhiZUowWVVraEYtU3FzVW94VXZfLVZSbGZ6bzlxUFhMYXJDR2czNk0wemxiNjU4WUtKSmtWZExTV2dMMTA5Z0tKY09NY0VhWTE5RFBIakNmYWVycVkzY2tlSVJpbm8?oc=5","date":"2025-12-11","type":"deal","source":"businesswire.com","summary":"Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI - businesswire.com","headline":"Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPS2VnNWdRMDF1UnpXVmRZMGZYLXhKbUNiNmt6Z042UE42RFNBaktIQ1hsUU9WMko1aWRSbUhBTkxkeVFmQ1p5UnhTUXk5MFZBSUVuUmk0cDF4ako5dVIzOHI0NUFMYmN5d0JEZldadWxFdGdYV2JBOXBUNTR0ZkRWb3NIWkY5dUcwdUl5SzJCdHJnTEtJTjVuU2RHSjQ1alB5UTYtSzlJeFdVUVVJZlJRTE1hWnJ1U0RJcEE?oc=5","date":"2025-09-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Basilea in line for $159m of US federal funding for UTI antibiotic pill - Pharmaceutical Technology","headline":"Basilea in line for $159m of US federal funding for UTI antibiotic pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1fa09EUmNNS0JOVUliaHRGd3Z2aVRzcURTS0J4ZlUyVS1BakE4aFRDazR3c29jMklxNS1WR1NncE1UU3QyOEJPdlByS3ZhNjVfM2tVeVlkQ2g1dmZ1ckZjOGV0YjdtbzdSclFGcFB0bDM?oc=5","date":"2025-09-09","type":"deal","source":"VISTA.Today","summary":"Malvern-Based Venatorx Enters Global Deal with Switzerland Pharma Company - VISTA.Today","headline":"Malvern-Based Venatorx Enters Global Deal with Switzerland Pharma Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPN1NZU21qendzNXRNNXpqNUtoSk5hV3M5UU12emUyaG5aV1pyLU5KR1VCdTlCMGJ6Vi1zWG5lckU2djh5eXNoLUdvZ3d3eUhPZmRubmFjWWctZnFQNFVwQ19FRDJqNG1UZGotaVo2YmNjeVBXdkxPZXhzbE9HRk9ydWxaVWtfZWdGbEZleEREWU1uNUw3cWR4cnJ4Ynd4MVRPOE01SnVTQWwweUJhdWRZZGtn?oc=5","date":"2025-09-04","type":"pipeline","source":"The Business Journals","summary":"Swiss pharma company Basilea bets up to $325M on Venatorx's experimental UTI treatment - The Business Journals","headline":"Swiss pharma company Basilea bets up to $325M on Venatorx's experimental UTI treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPNHdFejVlekRPS0VLd3B2VmNIMG9icHJ0cUpHcGhNdGVXWFNTZFgwS0NCbGtEZmlUdVNRcnBBVFVhLUROU0FJSlhCNE5JVUFXQjNKX1NyX1U2cmxvUzk5dVNqZzZLVUx0dUI1UDZCT2d0enpiY0F5XzBIbG53UGZLV1RfaE5WZDdyNV91MlM0a3YteEE0d3cxWHAtQ3pmWlpsSUk1eHFkUjVES2JUWjNyR2swd00yUQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Basilea secures rights to Venatorx’s antibiotic for complicated UTIs - Pharmaceutical Technology","headline":"Basilea secures rights to Venatorx’s antibiotic for complicated UTIs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPb2pIMjBLTnJTR2ZoRnBBRjFlbDBWSFFzSG9VREowZkM3cXlZREFENERiOUpSOHFEVklyUHNZbXoyV1lMWmZaV2RtbGlWbTBRSGVDVmppWk83UDBtRmtJeTJVcGxDYzVSOWo5V1JDY3NCUV9WX0JScXFNbDEyX2RQbms4andyUXBSQjNHMnRseWZiRXRmR1lJVHVFZXJNN0ZpbG9oelhCMWFNUnhqbjRCUEJ4TEhxY04xdDV5RkZkbVFHS2lwLW5mRnNIWHU1cXk0UF9yTGhjd2RkMm9TMVBZNk9vV1dONEk?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic - GlobeNewswire","headline":"Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQR2hjVlMwMHBUdUh0eWpxTHJkTWx1R19mYnJ4Qklaa0JMd2VDc3FyRWFST2hLNDJkLWl6VUZIQWpaV3FXTEFSX1BJYjJsZkM2c0FBdEwzRVJqV2tNeWlYVl9VTWtxZEJmdW51OG1wd2t4SW83d2Z5UFRaZzNQaFR2UUtnMmpNaWt6VkE?oc=5","date":"2024-04-04","type":"regulatory","source":"BioPharma Dive","summary":"FDA approves new antibiotic for several hard-to-treat infections - BioPharma Dive","headline":"FDA approves new antibiotic for several hard-to-treat infections","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPOVBibnVQRW0ydG1fNHBIc0FEd1UtSEJkWWc2SkpveHUxZWZwanN2T0xya2NXYXpwTXFybTQ4MWFMcmc1ZW5Cb3MtOTFVQVRuTmZjS1Rja1pZR25mQjI4UlJ0Z3NYeXhCNWFuSXVrNEtjNVVIT1h0VUFEaEwxMnViWFBYMlpLYmpZdTBlRW1xVjA1TDFTazJpM2wxRk5JTEJsN3E2blJhdlFqTTdRR0hTVFlhZUpuTFAzd0VOQU1R?oc=5","date":"2024-04-03","type":"regulatory","source":"Reuters","summary":"US FDA approves Basilea Pharmaceutica's antibiotic - Reuters","headline":"US FDA approves Basilea Pharmaceutica's antibiotic","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNMmh4UHVrRDJ0NlhKTjhBQ0lKX1FpRGpHM2RDR3ZYX0RVZkVyalVCNTdsQk9sMjhPT3pEUmNsd2JWcTJmM3VSRFJwQ3YteU81U2s3S1QxWlFTV25EOXFWOHlCNjNrTkNlS1JNb0ltUUYzYng1WFRUSHJFM0k5bDAya0Fsbk0wNUx0aXRVMVJhWjJGa0RVdWctTmFmdVhEWE1RR3NfNncxZjZacEdCSkRNaFQ2RQ?oc=5","date":"2023-11-13","type":"pipeline","source":"Fierce Biotech","summary":"Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal - Fierce Biotech","headline":"Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBDMGYwU2dkaHM1QjZwSjN4Tk9zOHpwYmp1QnV0VTM4YzZRY0FIX0dUc2VkMTFvQzMtUVlWX28zY1p3bUJWQ1ZVMFkxTnlZQ3RCMzFiNFVUYjlyeFJiNWJHd3pkUVZQMzQyS2VESDhR0gFyQVVfeXFMTUM3blI2TFI5Qmg0VHZDVGZCd1V3NTFfM3BSbFlDNDBHMktWdnM3Qk1POGw2RkFLY1lRRjFjWlpTMVVvcEJnWFFEUkNWUTJ0TllFaktTWmRRX2hCb1RLR3JvT1lSel9LZ3N0QU1DZTBuTE1B?oc=5","date":"2023-11-01","type":"deal","source":"koreabiomed.com","summary":"iNtRON Biotechnology signs conditional license agreement with Basilea for antibacterial drug - koreabiomed.com","headline":"iNtRON Biotechnology signs conditional license agreement with Basilea for antibacterial drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}